Arthroscopic Acetabular Labral Repair in Patients Over the Age of 60 Years: A Matched Case-Control Study.
To report the results of labral repair in a population of patients older than 60 years and compare these with a matched population of younger adults. We compared 21 consecutive patients older than 60 years undergoing labral repair with minimum 1-year follow-up with a contemporaneous group of 21 patients aged 18 to 55 years matched for sex, degree of chondral damage, and associated femoroacetabular impingement or dysplasia. Follow-up averaged 18.9 months (range, 12-24 months). The average age in the study group was 63.2 years (range, 61-71 years), and 20 patients had femoroacetabular impingement whereas 1 had dysplasia. Of these patients, 19 had acetabular articular damage (grade IV in 2, grade III in 11, grade II in 5, and grade I in 1) and 6 had femoral changes (grade IV in 1 and grade III in 5). The average age in the control group was 35.8 years (range, 20-54 years). We found average improvements of 28.1 points for the modified Harris Hip Score and 37.5 points for the International Hip Outcome Tool score within the study group and 21.2 points for the modified Harris Hip Score and 37.1 points for the International Hip Outcome Tool score within the control group. No statistically significant difference between the 2 groups was noted in the amount of improvement, with statistically and clinically significant improvements noted in both. Two study group patients underwent total hip arthroplasty (THA) at an average of 10 months, with 1 control group THA at 11 months. All 3 patients with conversion to THA had combined grade IV acetabular and grade III femoral damage. No repeated arthroscopies were performed and no complications occurred in either group. Patients older than 60 years can benefit from arthroscopic labral repair with improved outcomes, a modest rate of conversion to THA, and a small risk of complications. The results are comparable to those of younger adults. Combined bipolar grade IV and grade III articular damage may be a harbinger of conversion to THA regardless of age. Level III, comparative therapeutic trial.